Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy

Table 3

HP-eradication: univariate analysis of symptom regression.

Symptoms	L. reuteri group	No L. reuteri group	𝑃 value
Nausea	32 (66.7%)	45 (100%)	<0.001
Moderate-severe nausea	19 (42.2%)	45 (100%)	<0.001
Abdominal pain	29 (64.4%)	31 (68.9%)	0.655
Moderate-severe abdominal pain	6 (13.3%)	12 (26.7%)	0.114
Diarrhoea	10 (22.2%)	26 (57.7%)	<0.004
Moderate-severe diarrhoea	4 (10%)	15 (57.6%)	<0.001
Bloating	35 (77.7%)	37 (82.2%)	0.598
Moderate-severe bloating	12 (26.7%)	8 (17.8%)	0.310
Loss of appetite	36 (80%)	33 (73.3%)	0.455
Moderate-severe loss of appetite	11 (24.4%)	15 (33.3%)	0.352
Vomiting	17 (37.8%)	15 (33.3%)	0.660
Moderate-severe vomiting	3 (6.7%)	3 (6.7%)	1.000
Epigastric pain	5 (11.1%)	4 (8.9%)	0.725
Taste disturbance	6 (13.3%)	8 (17.8%)	0.561
Skin rash	4 (8.9%)	4 (8.9%)	1.000
Constipation	8 (17.8%)	11 (24.4%)	0.438